Comparative Pharmacology
Head-to-head clinical analysis: FERNDEX versus NEXESTA FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERNDEX versus NEXESTA FE.
FERNDEX vs NEXESTA FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferndex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
Norepinephrine-dopamine reuptake inhibitor (NDRI); weakly inhibits serotonin reuptake. Also releases norepinephrine from presynaptic neurons.
Adults: 100 mg orally three times daily.
One tablet (containing 1 mg norethindrone acetate and 1.5 mg ethinyl estradiol) orally once daily for 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged to 24-30 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Terminal half-life: 4-6 hours; clinical context: dosing every 4-6 hours for pain.
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <10%.
Renal: 20-30% unchanged; fecal/biliary: 70-80% as metabolites.
Category C
Category C
Iron Supplement
Iron Supplement